Medical oxygen usage jumped 516% in 43 days

NAGPUR : A staggering 516% jump in medical oxygen use in 43 days between February 21 and April 4 this year underlines the severity of the Covid infection spread in the district.

Data released by Food and Drugs Administration (FDA) showed that oxygen consumption was 19 metric tonne on February 21 this year. On Sunday (April 4), the data revealed consumption of 117 metric tonne medical oxygen. The rise had been steady and uniform over the period with the steepest jump registered between March 25 and March 26 when it had increased from 81 metric tonne to 91 metric tonne followed by another seven metric tonne (98 MT) on the following day, i.e. March 27.

In view of the scarcity and growing demand vis-à-vis shooting number of Covid patients requiring hospitalization, district collector Ravindra Thakare had instructed the lone liquid oxygen manufacturing unit of Nagpur — Inox Air Production Private Limited — to produce and supply the gas only for medical use by suspending production of industrial grade oxygen.

FDA authorities, under joint commissioner Mahesh Gadekar and assistant commissioner PM Ballal, too have suggested judicious use of oxygen by the hospitals.

Strict monitoring of production, supply and proactive measures like getting supply from Bhilai by FDA and the central control room did now allow oxygen stock to dwindle so far, said sources.

Despite high demand, the balance stock of oxygen in the district has remained around 142 metric tonne. Though the production had decreased from around 182 MT on March 3 to 174 MT on March 4, the increased outsourcing of around 67 MT had led to an optimum stock position.

“We are exploring all options to save and supply oxygen to hospitals so that there is no shortage, but at the same time we cannot afford over-stocking. The hospitals have been told to conduct checking of their oxygen supply mechanisms,” said a FDA source, adding oxygen audit at the hospitals is set to kick start soon.

  • Related Posts

    Commissioner FDA reviews enforcement measures

    Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices